top of page

PrIMAVeRa participates in AMR Accelerator Cross-Project Meeting 2024

March 2024

The Cross-Project Meeting gathered nearly 40 participants representing 9 Innovative Health Initiative (IHI)-funded projects from the AMR Accelerator on 05 March, in Basel, Switzerland.

Irina Meln (European Vaccine Initiative) and Federica Toffalini (GSK)
Irina Meln (EVI) and Federica Toffalini (GSK)

The PrIMAVeRa project, aiming to demonstrate the value of vaccines against antimicrobial resistance (AMR), was represented by Federica Toffalini from GSK, Irina Meln from European Vaccine Initiative (EVI), and Zainab Blattmann-Mahdi from Pfizer. Each project presented recent project outputs and impacts. PrIMAVeRa updated about the successful publication of 3 systematic reviews and discussed the findings from them, recent progress in model development and highlighted difficulties and plans for data collection.


Meeting highlights

Each project presented recent project outputs and impacts, and participated in discussions with representatives of other projects under the AMR Accelerator umbrella.  

A useful resource was shared during the ScientificInterest Group “Navigating the Regulatory Landscape: from Global Influences to Local Engagement”. Nathalie Seigneuret from IHI shared the latest guidelines on how to best interact with regulators from a public-private partnership umbrella in her presentation: “Engaging with regulators | IHI Innovative Health Initiative (”.

Damiano De Felice from CARB-X presented on another important topic: “How Push and Pull incentives contribute to antimicrobial innovations to address AMR”.

The PrIMAVeRa project team is grateful to the COMBINE team for organising a dynamic meeting and look forward to attending next year.

For more information, please visit the PrIMAVeRa project website ( and access the interactive webpages dedicated to the systematic review results hosted by the ECRAID-Base EPI-Net (


Media Contact:

Romina Di Marzo

Communications and Advocacy Manager


Irina Meln

Project Leader


This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the author's view, and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.



bottom of page